ContraFect Reports Second Quarter 2021 Financial Results and Provides Business Update
Multiple peer-reviewed journal publications and presentations at scientific forums drive value and recognition across the Company’s DLA portfolio Continued patient enrollment in ongoing Phase 3 DISRUPT study of exebacase YONKERS, N.Y., Aug. 13, 2021 (GLOBE more...
Bio-Path Holdings Reports Second Quarter 2021 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Aug. 13, 2021 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to more...
Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Awards
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 13, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine more...
Cidara Therapeutics (CDTX) Q2 Earnings and Revenues Surpass Estimates
Cidara Therapeutics (CDTX) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of a loss of $0.27 per share. This compares to loss of $0.45 per share a year ago. more...
CorMedix (CRMD) Reports Q2 Loss, Lags Revenue Estimates
CorMedix (CRMD) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.14 per share a year ago. These figures more...
Mustang Bio Collaborates with Mayo Clinic on Novel CAR T Technology
The exclusively licensed platform has potential application for any tumor target Preclinical development to continue at Mayo Clinic Mustang to file IND upon identification of a lead CAR construct WORCESTER, Mass., Aug. 12, 2021 (GLOBE more...
Cidara Provides Corporate Update and Reports Second Quarter 2021 Financial Results
SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today more...
Citius Pharmaceuticals, Inc. Reports Third Fiscal Quarter 2021 Financial Results and Provides General Business Update
Citius Pharmaceuticals, Inc. Reports Third Fiscal Quarter 2021 Financial Results and Provides General Business Update $115.7 million in cash and cash equivalents as of June 30, 2021 to develop pipeline and invest in long-term growth more...
EyeGate Pharma Reports Second Quarter 2021 Financial Results and Provides Business Update
WALTHAM, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the more...
CymaBay Reports Second Quarter and Six Months Ended June 30, 2021 Financial Results and Provides Corporate Update
Secured up to $100 million of additional development funding through a non-dilutive financing transaction with Abingworth Funds the Phase 3 development program for seladelpar in primary biliary cholangitis (PBC), including the Phase 3 RESPONSE clinical more...